Svetlana Yu. Vorotnikova

Svetlana Yu. Vorotnikova

Auto-generated profile, based on publicly available information

Svetlana Yu. Vorotnikova

Federal State Budgetary Institution «National Medical Research Center for Endocrinology named after academician I.I. Dedova» of the Ministry of Health Russian Federation

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2023 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
IDI. I. Dedov
I. I. Dedov
GMG. A. Melnichenko
G. A. Melnichenko
LDLarisa K Dzeranova
Larisa K Dzeranova
EAE. N. Andreeva
E. N. Andreeva
EGElena Grineva
Elena Grineva
LSL. A. Suplotova
L. A. Suplotova
Hyperprolactinemia is a persistent excess of the blood serum prolactin. The syndrome contains various symptoms, the most characteristic is a violation of the reproductive system. There are multiple endogenous and exogenous causes of hyperprolactinemia. The main treatment method is dopamine agonist therapy, in case of prolactinoma existence, surgical and radiation methods can be applied. About 15% of patients are resistant to dopamine agonist therapy, which determines creation of individual management tactics. The article presents a draft of clinical guidelines for the diagnosis and treatment of hyperprolactinemia, which provides a modern examination algorithm, discusses the basic principles of diagnostics and treatment approaches.

26 June 2024 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
EPElena Przhiyalkovskaya
Elena Przhiyalkovskaya
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
ETEkaterina Troshina
Ekaterina Troshina
GMG. A. Melnichenko
G. A. Melnichenko
IDI. I. Dedov
I. I. Dedov
ЮТЮ. Ю. Трунин
Ю. Ю. Трунин
We recommend acromegaly to be ruled in all patients with characteristic changes in appearance (A3). In all patients without characteristic changes in appearance, we recommend to rule out acromegaly, if several clinical signs suspicious for acromegaly are present (B3). We recommend acromegaly to be ruled out in all patients with pituitary adenoma (B3). We recommend to rule out acromegaly in all patients with prolactin-secreting adenomas (C4). For laboratory confirmation of acromegaly, we recommend to measure serum insulin-like growth factor-1 (IGF-1, somatomedin C) level (A3). In patients without obvious clinical signs of acromegaly and/or with a moderate increase in IGF-1 levels (IGF-1 index less than 1.3), we recommend to assess the response of somatotropic hormone (GH) to hyperglycemia (GH during an oral glucose tolerance test) (B3). In all patients with biochemically confirmed acromegaly, magnetic resonance imaging of the pituitary gland with intravenous contrast is recommended to assess pituitary adenoma size, location and growth pattern (A3). We recommend to measure blood glucose and glycated hemoglobin in all patients with confirmed acromegaly (B3). We recommend to measure serum prolactin levels in all patients with acromegaly (B3).In all patients with acromegaly and pituitary adenoma, transnasal transsphenoidal adenomectomy is recommended as first-line treatment if the patient’s consent is given and there are no contraindications (A1). For all patients with acromegaly for whom neurosurgical treatment is indicated, surgical intervention is recommended in medical centers, specializing in pituitary diseases, by neurosurgeons who perform at least 50 such operations per year (A3). We recommend that morphological and immunohistochemical examination of the removed pituitary adenoma is performed in all patients with acromegaly (A3). We do not recommend routine medical therapy for acromegaly before surgery as a mean to reduce tumor size (B2).For patients with acromegaly in whom neurosurgical treatment is not indicated or ineffective or while patient awaiting for the effect of radiation therapy, we recommend medical therapy (A1). Long-acting first-generation somatostatin analogues are recommended as first-line drug therapy for acromegaly. In case of partial/complete resistance to or intolerance to somatostatin analogs, pegvisomant is recommended as a second-line medical therapy for acromegaly (A1). We recommend starting pegvisomant from a single dose of 40–80 mg per day subcutaneously, then continue injections at a starting dose of 10 or 15 mg per day with IGF-1 monitoring after 4–6 weeks and dose adjustment if necessary (B2). In patients with acromegaly and a moderate increase in IGF-1 levels, we recommend to initiate cabergoline as medical monotherapy or, if somatostatin analogs are ineffective, in combination with them (B2).In patients with acromegaly, if the disease remains active after surgical treatment, if drug treatment is unavailable, intolerable or ineffective, and repeated neurosurgical intervention is inappropriate, it is we recommend radiation therapy (A1). A multidisciplinary approach is recommended in the management of acromegaly complications (C3).

25 February 2023 in Problems of Endocrinology
Verified
Journal Article
Open access
PDF file
LDLarisa K Dzeranova
Larisa K Dzeranova
ADA. V. Dorovskikh
A. V. Dorovskikh
EPEKATERINA PIGAROVA
EKATERINA PIGAROVA
ALA. M. Lapshina
A. M. Lapshina
SVS. Y. Vorotnikova
S. Y. Vorotnikova
VAV. N. Azizyan
V. N. Azizyan
Cyclic Cushing’s syndrome is a pathological condition characterized by alternating periods of excessive cortisol secretion with corresponding clinical manifestations and periods of spontaneous remission of the disease.To diagnose Cyclic Cushing’s syndrome it is necessary to record at least three episodes of excessive cortisol secretion alternating with periods of normalization of its production.In most cases, this pathology is diagnosed in patients with ACTH-secreting pituitary tumor, however, there are rare cases of cyclic hypercorticism with ectopic ACTH secretion by tumors of different localization and without verification of pathological hormonal secretion focus. In addition, cyclic hyperproduction of cortisol can be also observed in ACTH-independent Cushing’s syndrome associated with the presence of corticosteroma or adrenal hyperplasia. The exact causes and mechanisms of the cyclic hypercorticism are currently insufficiently studied.Due to the atypical course of the disease, the unpredictability of the occurrence of a new «cycle», the variability of its duration and manifestations (not only in different patients, but also in the same patient), verification of the diagnosis and determination of treatment tactics may be difficult in the daily practice of specialists, and the prevalence of this condition can be undervalued.

14 November 2023 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
LDLarisa K Dzeranova
Larisa K Dzeranova
SVS. Y. Vorotnikova
S. Y. Vorotnikova
ASA. S. Shutova
A. S. Shutova
EPEKATERINA PIGAROVA
EKATERINA PIGAROVA
MYM. I. Yevloyeva
M. I. Yevloyeva
One of the causes of non-tumor related hyperprolactinemia is taking a medications. Physicians of various specialties, such as cardiologists, gastroenterologists, endocrinologists, and neurologists, encounter hyperprolactinemia as a side effect of drug therapy in their practice, but it is most often observed in the practice of a psychiatrist when treating patients with psychotropic medications. Over the past few years, there has been an increase in the frequency of prescriptions of antidepressants and neuroleptics due to post-COVID-19 syndrome, anxiety and stress caused by the pandemic of a new coronavirus infection. There is also a predisposition to the development of hyperprolactinemia on the background of taking neuroleptics due to genetic features of patients. Currently, there is no established common algorithm for diagnosis and treatment of drug-induced hyperprolactinemia in the world. Based on a review of foreign and domestic literature, the article discusses in detail the mechanisms of development and various approaches to the correction of iatrogenic (drug-induced) hyperprolactinemia, assesses the prolactogenic activity of neuroleptics, and proposes algorithms for prolactin monitoring and correction of hyperprolactinemia using dopamine agonists. Often the tactics of management of such patients need to be discussed by a team of specialized physicians.

16 September 2019 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
ZKZilya A. Kalmykova
Zilya A. Kalmykova
SVSvetlana Y. Vorotnikova
Svetlana Y. Vorotnikova
NFNatalia S. Fedorova
Natalia S. Fedorova
LDLarisa K Dzeranova
Larisa K Dzeranova
EPEKATERINA PIGAROVA
EKATERINA PIGAROVA
Alexander V. VorontsovAlexander V. Vorontsov
Alexander V. Vorontsov
Hyperprolactinemia (HP) is one of the most common neuroendocrine disorders. In 60% of cases, pathological HP is caused by pituitary prolactin-secreting adenoma. Therapy with agonists of dopamine type 2 receptors (D2 receptor agonists) is a method of choice for the treatment of pathological HP which allows to achieve prolactin normalization and reduction of pituitary adenoma in most cases. However, 15-20% of patients are resistant to D2 receptor agonists, and the question of overcoming this resistance is highly relevant. Different approaches are considered to solve this problem, one - is to increase the dose of D2 receptor agonists up to the maximally tolerated. In this article, we present a clinical observation of a patient with a partial resistance to D2 receptor agonists who demonstrated a good response to treatment with high doses of cabergoline.

17 October 2018 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
LDLarisa K Dzeranova
Larisa K Dzeranova
NFNatalya S. Fedorova
Natalya S. Fedorova
SVSvetlana Yu. Vorotnikova
Svetlana Yu. Vorotnikova
EPEKATERINA PIGAROVA
EKATERINA PIGAROVA
Hyperprolactinemia is one of the most common endocrine diseases in the practice of different specialists. Interdisciplinary approach and unified principles of patient management are extremely relevant for this pathology due to the variety of clinical forms. The article demonstrates typical clinical manifestations of hyperprolactinemic syndrome on the example of three patients and shows the different approach to management and treatment.